At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SITC SITE Centers Corp.
Trading 04-02 11:29:59 EDT
12.74
+0.02
+0.16%
| High12.81 | Low12.62 | Vol78.34K |
| Open12.63 | D1 Closing12.72 | Amplitude1.45% |
| Mkt Cap667.96M | Tradable Cap632.36M | Total Shares52.43M |
| T/O996.84K | T/O Rate0.16% | Tradable Shares49.64M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
GlobeNewswire · 03-27
Press Release: CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
Dow Jones · 03-27
Press Release: TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
Dow Jones · 03-27
Press Release: Innate Pharma Reports Full Year 2024 Financial Results and Business Update
Dow Jones · 03-27
SITE Centers Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 03-26
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Newsfile · 03-20
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
GlobeNewswire · 03-13
Press Release: Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Dow Jones · 03-13
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
ACCESS Newswire · 03-13
Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Dow Jones · 03-13
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
GlobeNewswire · 03-06
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
Business Wire · 03-06
Press Release: Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
Dow Jones · 03-06
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire · 03-05
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
GlobeNewswire · 03-05
CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14
GlobeNewswire · 03-05
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
GlobeNewswire · 03-03
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
Business Wire · 03-03
SITE Centers Stock Declines on Q4 OFFO & Revenue Estimate Miss
Zacks · 02-28
SITE Centers Is Maintained at Overweight by Piper Sandler
Dow Jones · 02-28
Introduction
Company Name.
SITE Centers Corp.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
SITE Centers is an owner and manager of open-air shopping centers located in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App